Life-threatening Haemorrhage

Haemorrhage is still a major cause of death in trauma patients, despite the advances in trauma care management. The Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial results, which were published in 2010, show that tranexamic acid (TXA) reduces mortality in trauma patients with, or at risk of, bleeding, with no apparent increase in side effects.